Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interventional therapy plus sintilimab, bevacizumab, and icaritin vs interventional therapy plus sintilimab and bevacizumab in unresectable hepatocellular carcinoma
ChiCTR2500110058Phase 2Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab, bevacizumab and Icaritin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Conversion success rate. Started Sep 2025; status: recruiting.
02
Drugs
sintilimabbevacizumabIcaritin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500110058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110058.